Clinical safety of biosimilar recombinant human erythropoietins

Ivo Abraham, Karen MacDonald

Research output: Contribution to journalReview article

35 Scopus citations

Abstract

A "biosimilar" or "similar biological medicinal product" is a biological agent that is similar in terms of quality, safety, and efficacy to an authorized reference biological medicine. Since the expiration of the epoetin alfa patent in Europe, three agents have received marketing authorization from the European Medicines Agency: Binocrit (epoetin alfa; aka Abseamed and Epoetin Alfa Hexal), Retacrit (epoetin zeta; aka Silapo), and Eporatio (epoetin theta; aka Biopoin and Ratioepo). Areas covered: Using the EMA dossiers and journal publications, this article reviews clinical safety data for these products, with emphasis on serious/severe adverse events and a special consideration of immunogenicity, venous thromboembolism, and mortality. Expert opinion: A review of the available safety evidence shows that all three agents discussed have similar safety profiles. None were statistically higher on safety parameters to what is known about ESA as a class, when stratified by population. As with ESAs in general, immunogenicity, venous thromboembolism, and mortality are all concerns. What is known about ESAs regarding safety can be extended to biosimilar erythropoietins. Since biosimilars are unique, complex biological molecules, safety profiles may evolve from common to differentiated, once long-term product-specific safety data are available. Large-sample, long-term, observational studies of real-world practice will provide the heterogeneity and statistical power to demonstrate product-specific effectiveness and safety profiles. Statistically, out of the commercially available formulations of the three products reviewed, no single product is less or more safe.

Original languageEnglish (US)
Pages (from-to)819-840
Number of pages22
JournalExpert Opinion on Drug Safety
Volume11
Issue number5
DOIs
StatePublished - Sep 1 2012

Keywords

  • biosimilar pharmaceuticals
  • biosimilars
  • drug safety
  • erythropoietin
  • recombinant proteins
  • safety

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Clinical safety of biosimilar recombinant human erythropoietins'. Together they form a unique fingerprint.

  • Cite this